Specifically, there were similar incidences of hypoglycemia, urinary tract infections (UTI), genital infections, hypovolemia, and fractures observed between individuals treated with SGLT2 inhibitors and those administered a placebo (Mukai et al., 2021). Here, SLC5A2 is linked to Hypoglycemia.